截至6月3日收盘，重组蛋白概念上涨3.64%，位居概念板块涨幅第3，板块内，45股上涨，*ST万方涨 停，诺思兰德、科兴制药、海特生物等涨幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有 *ST苏吴、博瑞医药、西陇科学等，分别下跌4.78%、2.48%、1.42%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 | 3.08 | 一体化压铸 | -0.21 | | 眼 ...

Core Viewpoint - The cell immunotherapy sector has shown significant growth, with a 3.87% increase, ranking second among concept sectors, driven by strong performances from several stocks [1][2]. Group 1: Sector Performance - As of June 3, the cell immunotherapy concept saw 51 stocks rise, with notable gainers including Shutaishen and Guanhao Biological, both reaching a 20% limit up [1]. - Other top performers in the sector included Hainan Haiyao, Rui Zhi Pharmaceutical, and Zuo Li Pharmaceutical, with increases of 9.97%, 13.15%, and 10.66% respectively [1][2]. - Conversely, stocks like Xue Rong Biological, *ST Biological, and Fosun Pharmaceutical experienced declines of 1.76%, 1.14%, and 0.39% respectively [1]. Group 2: Capital Flow - The cell immunotherapy sector attracted a net inflow of 269 million yuan, with 34 stocks receiving significant capital inflows [2]. - Leading the net inflow was Huahai Pharmaceutical, which saw 266 million yuan enter, followed by Guanhao Biological and Hainan Haiyao with inflows of 159 million yuan and 64.85 million yuan respectively [2][3]. - The highest net inflow ratios were recorded for ST Zhongzhu, Hainan Haiyao, and Huahai Pharmaceutical, at 15.16%, 13.79%, and 12.53% respectively [3]. Group 3: Stock Specifics - Huahai Pharmaceutical had a daily increase of 7.63% with a turnover rate of 7.71% and a net capital flow of 266.08 million yuan [3]. - Guanhao Biological surged by 19.97% with a turnover rate of 28.68% and a net capital flow of 159.24 million yuan [3]. - Hainan Haiyao also performed well, increasing by 9.97% with a turnover rate of 6.18% and a net capital flow of 64.85 million yuan [3].

Core Viewpoint - The ophthalmology medical concept sector has shown a significant increase, with a rise of 3.08%, ranking it as the 10th highest among concept sectors, indicating strong market interest and investment potential in this area [1][2]. Group 1: Market Performance - As of June 3, the ophthalmology medical concept sector saw 42 stocks increase in value, with notable performers including Guanhao Biological, which hit a 20% limit up, and ST Zhongzhu, which also reached its limit up [1]. - Other top gainers in the sector included Nuo Si Lan De (up 18.82%), Hai Te Biological (up 13.18%), and Bei Da Pharmaceutical (up 7.34%) [1]. - Conversely, the sector experienced declines from companies such as Kanghong Pharmaceutical (down 2.16%), Chuangwei Digital (down 2.05%), and Jianghe Group (down 1.60%) [1]. Group 2: Capital Flow - The ophthalmology medical concept sector attracted a net inflow of 107 million yuan from major funds, with 25 stocks receiving net inflows, and 12 stocks exceeding 10 million yuan in net inflow [2]. - Guanhao Biological led the sector with a net inflow of 159 million yuan, followed by Bei Da Pharmaceutical (61.32 million yuan), Ma Ying Long (24.37 million yuan), and Hai Te Biological (21.22 million yuan) [2][3]. - The net inflow ratios for ST Zhongzhu, Huashen Technology, and Guanhao Biological were 15.16%, 13.41%, and 11.88%, respectively, indicating strong investor confidence in these stocks [3].

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry, specifically recommending an "Accumulate" rating for both the pharmaceutical manufacturing and pharmaceutical services sectors [1][2]. Core Insights - Continuous attention is suggested on innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug industry is experiencing a high demand for assets, with multinational corporations showing greater interest than concerns over geopolitical risks [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Monthly Portfolio Performance - The report highlights a monthly portfolio for June 2025, including companies such as Jiangsu Heng Rui Medicine, Huadong Medicine, and Sichuan Kelun Pharmaceutical, among others [5][36]. - In May 2025, the portfolio achieved an average increase of 7.7%, outperforming the overall pharmaceutical index, which rose by 4.5% [11][37]. Market Performance - In May 2025, the pharmaceutical sector ranked first in performance, with notable sub-sectors like chemical raw materials (+10.5%) and chemical preparations (+9.6%) showing strong growth [20][37]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. International Market Comparison - The Hong Kong pharmaceutical sector outperformed the market with a rise of 7.8%, while the U.S. pharmaceutical sector underperformed, declining by 5.7% [38]. - The report identifies top-performing stocks in both markets, with significant gains in the Hong Kong sector and notable declines in the U.S. sector [38].

6月3日，A股、港股市场集体上涨，创新药板块概念股持续走强。 相关ETF方面，截至收盘，创新药ETF天弘（517380）涨2.24%，年内累计涨幅达23.08%，位居全市场 行业类ETF涨幅第一，涨幅领先第二名超9%。成分股中，睿智医药涨超13%，亚盛医药-B涨超8%，华 海药业、联邦制药、和黄医药、贝达药业等股涨超7%。 创新药ETF天弘(517380)及联接基金(A类014564，C类014565)是全市场唯一一只跟踪恒生沪深港创新药 精选50指数的产品，该指数覆盖了沪、深、港三地创新药龙头，十大权重股包括百济神州、药明康德、 恒瑞医药、泰格医药等细分领域龙头，可谓是创新药"浓度"极高。同时，该ETF及联接基金（A类： 014564，C类：014565）采用量化指标优化，截至6月3日收盘，年内累计涨幅位居全市场行业类ETF涨 幅第一。 招银国际表示，我们认为，受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医 疗设备招标复苏、内需复苏等积极因素推动，医药行业有望在 2025 年继续迎来估值修复。 消息面上，据第一财经，5月30日，在陆家嘴金融沙龙上，中国科学院院士马大为表示，我们有越来越 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. - A total of 373 stocks (77.9%) in the sector rose last week, while 97 stocks (20.3%) declined. The top five gainers were Shuyou Shen (60.41%), Huason Pharmaceutical (41.97%), Changshan Pharmaceutical (35.91%), Huana Pharmaceutical (32.62%), and Yifang Biological (30.51%) [4][27]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the approval of 11 innovative drugs by the National Medical Products Administration (NMPA) on May 29, which enhances treatment options for patients and showcases the increasing innovation capability of China's pharmaceutical industry [5][29]. - The 2025 American Society of Clinical Oncology (ASCO) annual meeting showcased several domestic innovative drug projects, indicating that local companies are gaining international recognition for their innovative capabilities [5][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector as it is the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. Additionally, it recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][35]. - Recommended stocks include Beida Pharmaceutical, Te Bao Biological, Qianhong Pharmaceutical, Ling Rui Pharmaceutical, and Lao Bai Xing. Stocks to watch include Kelong Pharmaceutical, Rongchang Biological, Kaili Medical, Huaxia Eye Hospital, and Baipu Sais [6][35].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].

Group 1 - The A-share market opened positively in June, with the Shanghai Composite Index closing at 3361.98 points, up 0.43% [1] - The A500 Index ETF (159351) experienced a slight decline of 0.31% during the day but saw a net subscription of 45 million units [1] - The A500 Index ETF recorded a total trading volume of 2.79 billion yuan, ranking second among similar products in the market and first in the Shenzhen market, with a turnover rate of 18.93% [1] Group 2 - In May, the National Press and Publication Administration approved 130 domestic and 14 imported online games, totaling 144 approvals, setting a new monthly record in nearly two years [1] - Major gaming industry stocks surged following the news, with Changyou Technology rising over 14%, Giant Network nearly 7%, and Perfect World over 5% [1] - Pharmaceutical stocks also maintained strong performance, with Huahai Pharmaceutical and Betta Pharmaceuticals both increasing over 7% [1] Group 3 - Short-term market dynamics are influenced by a mix of internal and external factors, but policy support, profit recovery, and the attractiveness of RMB assets provide a foundation for stability [1] - Investment strategies are recommended to focus on "core assets as a shield and technology growth as a spear," while paying attention to policy implementation and industry catalysts in June [1] Group 4 - The A500 Index ETF (159351) tracks the CSI A500 Index, consisting of 500 stocks with large market capitalization and good liquidity, providing a tool for investors to access representative A-share companies [2] - Investors can also consider the A500 Index ETF linked funds (Class A 022453; Class C 022454) to capitalize on the upward potential of quality core assets [2]

Group 1 - As of May 31, 2025, the "old-for-new" program in five major consumer goods categories has driven sales of 1.1 trillion yuan, with approximately 175 million subsidies issued directly to consumers, enhancing consumer welfare and stimulating the consumption market [1] - The "old-for-new" initiative reflects the stability and potential of the Chinese economy, contributing to high-quality economic development [1] - On June 3, the A-share market experienced a pullback, with the A500 index showing stable performance and the A500 ETF (159339) averaging over 100 million yuan in daily trading volume over the past 10 trading days, indicating high market activity [1] Group 2 - The A500 index, which represents core A-share assets, covers 63% of total revenue and 70% of total net profit in the market with less than 10% of the total number of A-share stocks, making it a strong tool for long-term investment in China's capital market [1] - The A50 ETF (159592) tracks the A50 index, which includes large-cap leading stocks across various industries, benefiting from increased market concentration amid supply-side reforms [2] - The investment value of A-shares is gradually becoming apparent, particularly during the recovery of ROE and profit cycles, with record high dividends and buybacks since the beginning of the year [2]

Core Viewpoint - The recovery of A-share earnings growth in Q1 2025 alleviates previous investor concerns about a prolonged decline in the earnings cycle, suggesting a potential rebound in the earnings cycle driven by stabilizing high-dimensional variables such as capacity and real estate cycles [1] Group 1: Index Performance - As of June 3, 2025, the CSI 500 Quality Growth Index (930939) increased by 0.55%, with notable gains from constituent stocks such as Debang Co., Ltd. (603056) up 10.00%, Huahai Pharmaceutical (600521) up 6.94%, and BeiDa Pharmaceutical (300558) up 6.76% [1] - The CSI 500 Quality Growth ETF (560500) rose by 0.32%, with the latest price at 0.94 yuan [1] Group 2: Top Holdings - As of May 30, 2025, the top ten weighted stocks in the CSI 500 Quality Growth Index accounted for 23.79% of the index, including Chifeng Gold (600988) and Ninebot Company (689009) [2] - The top ten stocks by weight include Chifeng Gold (3.13%), Ninebot Company (2.71%), and Shenghong Technology (2.53%) among others [3]